After a 20% one-way decline in share price and unusual movements in holdings, when will GenFang Medicine-B (02595) see a rebound?

Since August 26, the share price of Jinfang Pharma-B (02595) has been on a steady downward trend, with a cumulative decline of nearly 20% over 13 trading days. Since August 26, the share price of

Zhitong FinanceSep 12 19:27

Goldman Sachs: Clear Recovery in China’s CRO/CDMO Sector; Bullish on WuXi AppTec, Pharmaron, Asymchem, Tigermed, and GenScript

Goldman Sachs released a research report stating that results for the second quarter and first half of the year indicate a clear recovery in China’s CRO/CDMO industry, with corporate earnings exceeding expectations, raised guidance, and strong order books. The firm assigned “Buy” ratings to Wuxi Apptec (02359.HK), Wuxi XDC (02268.HK), Asymchem (06821.HK), and Pharmaron (03759.HK), while assigning a “Neutral” rating to Wuxi Bio (02269.HK). Goldman Sachs covered Wuxi Apptec, Wuxi XDC, Wuxi Bio, Pharmaron, Asymchem, Tigermed (03347.HK), and GenScript (0

AASTOCKSSep 11 17:49

September 10 Buyback Roundup | Tencent and 3SBio, among others, conducted share buybacks, with Tencent spending HK$100 million

According to disclosure documents released by the Hong Kong Exchange on September 11, $Tencent(00700.HK)$ and $3SBio(01530.HK)$ repurchased shares. ① On September 10, $Tencent(00700.HK)$ repurchased 235,000 ordinary shares, involving an amount of HK$100 million, with the repurchase price per share ranging from HK$425.2 to HK$430.2. Since the resolution on the buyback mandate was passed, the cumulative number of securities repurchased stands at 44.8487 million shares, representing 0.49187% of the number of issued shares at the time the ordinary resolution was passed. ② $3SBio(01530.

Futu NewsSep 11 09:40

Jinfang Medicine-B (02595.HK) repurchased 80,000 shares on September 10 at a cost of HK$2.063 million.

Gelonghui, September 11 | GenFang Medicine-B (02595.HK) announced that on September 10, 2026, it repurchased 80,000 shares at a total cost of HK$2.063 million, with the repurchase price ranging from HK$25.32 to HK$26.00 per share.

Gelonghui FinanceSep 11 06:42

September 9 Buyback Roundup | Tencent, HSBC Holdings, and others conduct share buybacks, with Tencent spending HK$100 million

According to disclosure documents filed with the Hong Kong Exchange on September 10, companies including $Tencent (00700.HK)$ and $HSBC Holdings (00005.HK)$ repurchased shares. ① $Tencent (00700.HK)$ repurchased 231,000 ordinary shares on September 9, involving a total amount of HK$100 million, with repurchase prices ranging from HK$438.2 to HK$432.8 per share. Since the resolution authorizing share repurchases was passed, the cumulative number of securities repurchased stands at 44.6137 million shares, representing 0.48929% of the issued shares outstanding at the time the ordinary resolution was approved. ② $HSBC Holdings (00005.HK)$

Futu NewsSep 10 09:20

CLSA: China’s Innovative Drug Sector Returns to Alpha Dominance; Macro Volatility May Present Buying Opportunities

A report by CLSA indicates that China’s innovative drug sector is returning to a market driven primarily by company fundamentals and stock-specific alpha, with the influence of company-specific fundamentals—particularly business development (BD) and Phase III clinical progress—rising relative to macro factors (beta). Attribution analysis by the bank shows that the explanatory power of fundamentals for pharmaceutical stock price movements reached 82.7% from 2015 to 2021, fell to approximately 32.7% from 2021 to 2024, and has rebounded to over 54% since 2025, partly supported by BD developments and key overseas Phase III trials. The bank expects that, as market sentiment toward

AASTOCKSSep 9 12:08